Yes, @bobbler mentioned it, but I was still very surprised when I got to the Limitations section and read this:Half of their limitations section is like asking someone what their weaknesses are and them replying ‘well I’m somewhat of a high achiever’.
After some elaboration about that, more praises are sung.Limitations: The strengths of this study lie in the large, representative sample, the robust co-production with people with ME/CFS and clinicians working in NHS specialist ME/CFS services. The number of people with severe/very severe ME/CFS recruited is also a strength.
A further strength is the thoroughness with which the Rasch analysis was completed. It is unusual to see the complete cycle of scale development, analysis, empirical modification, and psychometric validation of the modified scale in a new cohort, and the conversion tables to
enable parametric analyses are rarely presented.
Finally they get to some 'possible' limitations.
That seems to be saying 'we mostly talked to middle-aged women who are quite ill and have been ill for a long time, but that's okay, because that is what everyone else does too, and therefore we are confident that we have sampled a reasonable representation of the ME/CFS community'. Aside from that making no logical sense, it doesn't even seem to have occurred to them that the people who will be filling out the survey mostly won't be middle-aged women who have 'extensive lived experience' of ME/CFS. I would have thought that it was important to test the survey on people new to the illness and the language that is used to describe symptoms. For all their extensive and obscure validation, it doesn't seem that they did that.Possible limitations lie in the representativeness of the sample. The literature regarding the demographics of ME./CFS are sparse, so it is not possible to compare our sample with an authoritative source of epidemiological data. However, our demographics broadly reflect other large ME/CFS studies with convenience samples31-34: predominantly middle-aged women with moderately severe illness and extensive lived experience. Thus, we are confident data are reasonably representative of the ME/ CFS community.
The one limitation that they whole heartedly get behind is that it hasn't been validated in children. I guess that's because that is another nice bit of fundable work there.